TRAIL death receptors as tumor suppressors and drug targets

Cell Cycle

Volumn 7, Issue 11, 2008, Pages 1525-1528

  Finnberg, Niklas ^a   El Deiry, Wafik S ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Drug target; Myc; p53; TRAIL R; Tumor suppressor

Indexed keywords

DEATH RECEPTOR; PROTEIN P53; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; B CELL LYMPHOMA; CELL SPECIFICITY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG TARGETING; GAMMA RADIATION; GENE LOCUS; GENE OVEREXPRESSION; GENETIC ENGINEERING; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIVER CELL CARCINOMA; LYMPHOMA; MOUSE; NICK END LABELING; NONHUMAN; ONCOGENE MYC; RECEPTOR BINDING; REVIEW; TUMOR SUPPRESSOR GENE; ZEBRA FISH;

DANIO RERIO; MUS;

EID: 45849115453     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.7.11.5975     Document Type: Review

References (51)

1. Finnberg N, Klein Szanto AJ, El-Deiry WS. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest 2008; 118:111-23.
2. Grosse Wilde A, et al. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest 2008; 118:100-10.
3. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2:420-30.
4. Boldin MP, et al. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 1995; 270:7795-8.
5. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81:505-12.
6. Bodmer JL, et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000; 2:241-3.
7. Kischkel FC, et al. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000; 12:611-20.
8. Sprick MR, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000; 12:599-609.
9. Yin XM, et al. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 1999; 400:886-91.
10. Cretney E, et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002; 168:1356-61.
11. Diehl GE, et al. TRAIL-R as a negative regulator of innate immune cell responses. Immunity 2004; 21:877-89.
12. Finnberg N, et al. DR5 knockout mice are compromised in radiation-induced apoptosis. Mol Cell Biol 2005; 25:2000-13.
13. Zerafa N, et al. Cutting edge: TRAIL deficiency accelerates hematological malignancies. J Immunol 2005; 175:5586-90.
14. Davis JE, Smyth MJ, Trapani JA. Granzyme A and B-deficient killer lymphocytes are defective in eliciting DNA fragmentation but retain potent in vivo anti-tumor capacity. Eur J Immunol 2001; 31:39-47.
15. Smyth MJ, et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000; 191:661-8.
16. Takeda K, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001; 7:94-100.
17. Schneider P, et al. Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol Chem 2003; 278:5444-54.
18. Chou AH, et al. Enhanced proliferation and increased IFN-gamma production in T cells by signal transduced through TNF-related apoptosis-inducing ligand. J Immunol 2001; 167:1347-52.
19. Yue HH, Diehl GE, Winoto A. Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice. Cell Death Differ 2005; 12:94-7.
20. Wu GS, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997; 17:141-3.
21. Finnberg N, et al. Non-invasive fluorescence imaging of cell death in fresh human colon epithelia treated with 5-Fluorouracil, CPT-11 and/or TRAIL. Cancer Biol Ther 2005; 4:937-42.
22. Hague A, et al. Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis. Br J Cancer 2005; 92:736-42.
23. Boivin GP, et al. Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 2003; 124762-77.
24. Clarke AR, Cummings MC, Harrison DJ. Interaction between murine germline mutations in p53 and APC predisposes to pancreatic neoplasia but not to increased intestinal malignancy. Oncogene 1995; 11:1913-20.
25. -/- mice. Carcinogenesis 2003; 24:217-24.
26. Quintanilla M, Brown K, Ramsden M, Balmain A. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 1986; 322:78-80.
27. Ruggeri B, et al. Benzo[a]pyrene-induced murine skin tumors exhibit frequent and characteristic G to T mutations in the p53 gene. Proc Natl Acad Sci USA 1993; 90:1013-7.
28. Adams JM, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318:533-8.
29. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999; 13:2658-69.
30. Hemann MT, et al. Suppression of tumorigenesis by the p53 target PUMA. Proc Natl Acad Sci USA 2004; 101:9333-8.
31. Schmitt CA, McCurrach ME, de SE, Wallace Brodeur RR, Lowe SW. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 1999; 13:2670-7.
32. Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990; 348:331-3.
33. Zornig M, Grzeschiczek A, Kowalski MB, Hartmann KU, Moroy T. Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV. Oncogene 1995; 10:2397-401.
34. Rubio Moscardo F, et al. Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. Blood 2005; 106:3214-22.
35. Dyer MJ, MacFarlane M, Cohen GM. Barriers to effective TRAIL-targeted therapy of malignancy. J Clin Oncol 2007; 25:4505-6.
36. Fei P, Bernhard EJ, El-Deiry WS. Tissue-specific induction of p53 targets in vivo. Cancer Res 2002; 62:7316-27.
37. Cip1 nullizygosity increases tumor metastasis in irradiated mice. Cancer Res 2003; 63:3021-5.
38. -/- mice. Nat Immunol 2003; 4:255-60.
39. Lamhamedi Cherradi SE, Zheng S, Tisch RM, Chen YH. Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes. Diabetes 2003; 52:2274-8.
40. Zheng SJ, Wang P, Tsabary G, Chen YH. Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J Clin Invest 2004; 113:58-64.
41. Herr I, Schemmer P, Buchler MW. On the TRAIL to therapeutic intervention in liver disease. Hepatology 2007; 46:266-74.
42. Takeda K, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002; 195:161-9.
43. Eimon PM, et al. Delineation of the cell-extrinsic apoptosis pathway in the zebrafish. Cell Death Differ 2006; 13:1619-30.
44. Higuchi H, Grambihler A, Canbay A, Bronk SF, Gores GJ. Bile acids upregulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1. J Biol Chem 2004; 279:51-60.
45. Kahraman A, et al. TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse. Hepatology 2008; In press.
46. Volkmann X, et al. Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology 2007; 46:1498-508.
47. Wiley SR, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3:673-82.
48. Kemp CJ, Sun S, Gurley KE. p53 induction and apoptosis in response to radio- and chemotherapy in vivo is tumor-type-dependent. Cancer Res 2001; 61:327-32.
49. Koschny R, et al. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res 2007; 13:3403-412.
50. Nguyen T, Zhang XD, Hersey P. Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Clin Cancer Res 2001; 7:966-73.
51. Sussman RT, Ricci MS, Hart LS, Sun SY, El-Deiry WS. Chemotherapy- resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4. Cancer Biol Ther 2007; 6:1490-5.